t
AOTI Inc. announced on August 4, 2026, that on August 3, 2026, its PDMRs Mike Griffiths (CEO), Jayesh Pankhania (CFO), and Anthony Moffatt (COO) acquired common shares via the Company's Employee Share Purchase Plan. CSC Global, acting as Trustee, purchased shares on their behalf on the London Stock Exchange. Griffiths acquired 918 shares, Pankhania 921 shares, and Moffatt 927 shares, all at a price of £0.975p per share.
| Date | 4 Aug 2026 |
| Time | 16:09:25 |
| Category | Director/PDMR dealings |
| ID | 2712P |
4 August 2026
AOTI INC. (the "Company")
Directors'/PDMR Shareholding - Employee Share Purchase Plan
The Company was informed on 3 August 2026, that the following purchases of AOTI, Inc. common shares were made by CSC Global1 on 3 August 2026 on behalf of certain of the Company's persons discharging managerial responsibilities ("PDMR") pursuant to the Company's Employee Share Purchase Plan ("ESPP").
Under the ESPP, participating employees make regular payroll contributions which are used to acquire shares in the Company. Further information regarding the ESPP can be found in the announcement of 1 May 2026.
1CSC Global operates through CSC Employee Benefit Trustee (Jersey) Limited and CSC Employee Benefit Services (Jersey) Limited
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||||||||||
|
a)
|
Name
|
Mike Griffiths Jayesh Pankhania Anthony Moffatt |
||||||||||||
|
2
|
Reason for the notification
|
|||||||||||||
|
a)
|
Position/status
|
1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Operating Officer
|
||||||||||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||||||||
|
a)
|
Name
|
AOTI Inc. |
||||||||||||
|
b)
|
LEI
|
213800ZGCNDSTWIRK687 |
||||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Common shares of $0.00001 each
ISIN: US03690C1027 |
||||||||||||
|
b)
|
Nature of the transaction
|
Purchase of common shares by the Trustee of the Employee Share Purchase Plan |
||||||||||||
|
c)
|
Price(s) and volume(s) |
|
||||||||||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
NA
NA |
||||||||||||
|
e)
|
Date of the transaction
|
3 August 2026 |
||||||||||||
|
f)
|
Place of the transaction
|
London Stock Exchange |
||||||||||||
END
|
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
|
Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden
|
+44 (0)20 3100 2000
|
|
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins
|
+44 (0)20 3727 1000
|
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent. reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net